Md Yuzaiful Md Yusof Yuz6Yusof
1 week ago
#EULAR2026 OP Are we closer to controlled trials of CAR-T? Miv-cel KYV-101 autologous CD19 CAR-T reported efficacy and safety profile in 6 patients with severe refractory #RA (median prior bDMARDs: 6) in Phase I COMPARE. Will proceed to Phase II with RTX as a comparator @RheumNow https://t.co/Rb4BFgBDZE
Jiha Lee JihaRheum
1 week ago
MTX PO split dose MTX (15mg AM + 10mg PM) vs SC in early seropositive #RA in SCOOT RCT (n=252): SC MTX had better EULAR response at 16 wks (OR 0.55, p=0.049) and ↑ transaminitis with oral split. SC MTX remains the preferred route above 15mg/wk. @RheumNow #EULAR2026 OP0206
Md Yuzaiful Md Yusof Yuz6Yusof
1 week ago
#EULAR2026 OP0166 In a phase III RCT in dermatomyositis, brepocitinib, first in class selective SyK-i and JAK1-i showed rapid meaningful improvement in cutaneous DM as early as Week 4 vs PBO. Exciting option and is under FDA Priority Review for approval @RheumNow #EULARBest https://t.co/9b0WurgBkN
Janet Pope Janetbirdope
1 week ago
#Rosnilimab works!! #PD1 agonist
In #moderate to severe #RA showed fast deep responses in Ph2 #PBO CONTROLLED #rheumatoid #athritis
Seemed NOT to have sig side effects compared to some PD1 drugs that ceased development in RA
#EULAR2026 @RheumNow
#OP0202 #EULARbest https://t.co/Jz92npXdgd
People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of comorbidities, from cardiovascular diseases to cognitive impairment and fractures. The 2026 EULAR Congress showcased new data and ideas around various comorbidities and drug safety issues in people with an RMD – highlighting the need for integrated care. Here are five abstracts to consider.
Jiha Lee JihaRheum
1 week ago
Does ASA protect against JAKi-associated VTE in #RA? Swedish data (n=26,116): No. JAKi VTE risk remained elevated vs TNFi regardless of concomitant ASA or DOAC use. NSAIDs showed a non-significant trend toward protection. @RheumNow #EULAR2026 POS0068
The first day of EULAR 2026 in London featured the opening ceremonies, a plenary session, posters nd the first round of major oral presentations to an audience of nearly 15,000 attendees. Here are a few of my favorites from the first day.
Few topics in rheumatology have reshaped prescribing behaviour as dramatically as the safety concerns surrounding JAK inhibitors following ORAL Surveillance and the subsequent FDA and EMA warnings.
Aurelie Najm AurelieRheumo
1 week 1 day ago
Izokibep IL-17A Affibody PsA
343 pts RCT PBO crossover wk16
52 wks data
ACR50 50–57% ACR70 36–42% PASI100 64% MDA 47–52%
No diff between QW vs Q2W
AE Injection-site reactions, URTIs most common
No new safety signals
Looks like any other IL17Ai to me
#EULAR2026 #OP073 https://t.co/WiHT8Plitn
Mrinalini Dey DrMiniDey
1 week 1 day ago
Cancer risk with JAK inhibitors remains a major focus at #EULAR2026. In #OP086, analysis from 14 international RA registries and >60000 treatment courses found no statistically significant increase in overall or subtype-specific malignancy risk with JAKi versus TNFi. @RheumNow https://t.co/JeOmTufYwo
Mrinalini Dey DrMiniDey
1 week 1 day ago
#OP085 from Sweden adds more real-world data to the JAKi safety discussion at #EULAR2026. In >26000 RA treatment initiations, JAKis were associated with higher VTE risk vs TNFi (HR 1.89), with similar findings persisting in 2021-2024 data. @RheumNow https://t.co/YRjPNZ8mmo
Nelly ZIADE 🍀 Nellziade
1 week 1 day ago
💉 Risankizumab durable in #PsA?
#POS0047 3 RCT n=964 KEEPsAKE
Yes! ACR50 ~37% & MDA ~34% @w244
no new safety signals 💪
#EULAR2026 @RheumNow https://t.co/911Fi9vxfP
Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare. Recent anecdotal reports suggest that CD19-directed chimeric antigen receptor T (CAR-T) cell therapy may be an effective approach.
Md Yuzaiful Md Yusof Yuz6Yusof
1 week 1 day ago
#EULAR2026 POS0044 TO ASPIRIN OR NOT in asymptomatic antiphospholipid antibodies (aPL) carriers? A study in Spain reported 4.6% VTE & 4.1% ATE.
-Aspirin reduced thrombosis without increasing bleeding risk in asymptomatic aPL inc. those <3 lab points (isolated LA) @RheumNow https://t.co/NyVjAfjAKd
